磷霉素治疗耐甲氧西林金黄色葡萄球菌所致实验性骨髓炎的疗效。
Efficacy of fosfomycin in experimental osteomyelitis due to methicillin-resistant Staphylococcus aureus.
机构信息
Department of Internal Medicine I, Division of Infectious Diseases, Medical University of Vienna, Vienna, Austria.
出版信息
Antimicrob Agents Chemother. 2011 Feb;55(2):931-3. doi: 10.1128/AAC.00881-10. Epub 2010 Nov 22.
Abstract
The activity of fosfomycin was evaluated in an experimental methicillin-resistant Staphylococcus aureus (MRSA) osteomyelitis model. Eighteen rats were treated for 4 weeks with 150 mg of fosfomycin/kg of body weight intraperitoneally once daily or with saline placebo. After treatment, animals were euthanized and the infected tibiae were processed for quantitative bacterial culture. Bone cultures were positive for methicillin-resistant S. aureus in all 9 (100%) untreated controls and in 2 of 9 (22.2%) fosfomycin-treated rats. Thus, fosfomycin treatment was significantly more efficacious than placebo. No development of resistance was observed after the 4-week treatment period.
摘要
磷霉素的活性在耐甲氧西林金黄色葡萄球菌（MRSA）骨感染模型中进行了评估。18 只大鼠接受了为期 4 周的治疗，每天腹腔内注射 150mg/kg 体重的磷霉素或生理盐水安慰剂。治疗后，动物被安乐死，感染的胫骨进行定量细菌培养。未经治疗的对照组中，有 9 只（100%）和接受磷霉素治疗的大鼠中，有 2 只（22.2%）的骨培养物对耐甲氧西林金黄色葡萄球菌呈阳性。因此，磷霉素治疗明显比安慰剂更有效。在 4 周的治疗期间没有观察到耐药性的发展。
相似文献
1
Efficacy of fosfomycin in experimental osteomyelitis due to methicillin-resistant Staphylococcus aureus.
Antimicrob Agents Chemother. 2011 Feb;55(2):931-3. doi: 10.1128/AAC.00881-10. Epub 2010 Nov 22.
2
Daptomycin, fosfomycin, or both for treatment of methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model.
Antimicrob Agents Chemother. 2011 Nov;55(11):4999-5003. doi: 10.1128/AAC.00584-11. Epub 2011 Aug 22.
3
Efficacy of fosfomycin compared to vancomycin in treatment of implant-associated chronic methicillin-resistant Staphylococcus aureus osteomyelitis in rats.
Antimicrob Agents Chemother. 2014 Sep;58(9):5111-6. doi: 10.1128/AAC.02720-13. Epub 2014 Jun 16.
4
Daptomycin plus fosfomycin, a synergistic combination in experimental implant-associated osteomyelitis due to methicillin-resistant Staphylococcus aureus in rats.
Antimicrob Agents Chemother. 2015 Feb;59(2):859-63. doi: 10.1128/AAC.04246-14. Epub 2014 Nov 17.
5
Therapeutic potential of dalbavancin in a rat model of methicillin-resistant Staphylococcus aureus (MRSA)-osteomyelitis.
Int J Antimicrob Agents. 2020 Jul;56(1):106021. doi: 10.1016/j.ijantimicag.2020.106021. Epub 2020 May 18.
6
High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis.
Antimicrob Agents Chemother. 2012 Aug;56(8):4511-5. doi: 10.1128/AAC.06449-11. Epub 2012 May 29.
7
Activity of Tedizolid in Methicillin-Resistant Staphylococcus aureus Experimental Foreign Body-Associated Osteomyelitis.
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6568-6572. doi: 10.1128/AAC.01248-16. Print 2016 Nov.
8
Vertebral osteomyelitis caused by vancomycin-tolerant methicillin-resistant Staphylococcus aureus bacteremia: Experience with teicoplanin plus fosfomycin combination therapy.
J Microbiol Immunol Infect. 2016 Aug;49(4):600-3. doi: 10.1016/j.jmii.2013.09.002. Epub 2013 Nov 21.
9
Efficacy of telavancin in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis: studies with a rabbit model.
J Antimicrob Chemother. 2009 Feb;63(2):357-60. doi: 10.1093/jac/dkn490. Epub 2008 Dec 5.
10
Treatment of implant-related methicillin-resistant Staphylococcus aureus osteomyelitis with vancomycin-loaded VK100 silicone cement: An experimental study in rats.
J Orthop Surg (Hong Kong). 2018 Jan-Apr;26(1):2309499017754093. doi: 10.1177/2309499017754093.
引用本文的文献
1
The role of fosfomycin in osteoarticular infection.
Rev Esp Quimioter. 2019 May;32 Suppl 1(Suppl 1):30-36.
2
Fosfomycin enhances phagocyte-mediated killing of Staphylococcus aureus by extracellular traps and reactive oxygen species.
Sci Rep. 2016 Jan 18;6:19262. doi: 10.1038/srep19262.
3
Testing the mutant selection window hypothesis in vitro and in vivo with Staphylococcus aureus exposed to fosfomycin.
Eur J Clin Microbiol Infect Dis. 2015 Apr;34(4):737-44. doi: 10.1007/s10096-014-2285-6. Epub 2014 Nov 26.
4
Daptomycin plus fosfomycin, a synergistic combination in experimental implant-associated osteomyelitis due to methicillin-resistant Staphylococcus aureus in rats.
Antimicrob Agents Chemother. 2015 Feb;59(2):859-63. doi: 10.1128/AAC.04246-14. Epub 2014 Nov 17.
5
High activity of Fosfomycin and Rifampin against methicillin-resistant staphylococcus aureus biofilm in vitro and in an experimental foreign-body infection model.
Antimicrob Agents Chemother. 2014 May;58(5):2547-53. doi: 10.1128/AAC.02420-12. Epub 2014 Feb 18.
6
Activities of fosfomycin and rifampin on planktonic and adherent Enterococcus faecalis strains in an experimental foreign-body infection model.
Antimicrob Agents Chemother. 2014;58(3):1284-93. doi: 10.1128/AAC.02583-12. Epub 2013 Oct 21.
7
Activities of fosfomycin, tigecycline, colistin, and gentamicin against extended-spectrum-β-lactamase-producing Escherichia coli in a foreign-body infection model.
Antimicrob Agents Chemother. 2013 Mar;57(3):1421-7. doi: 10.1128/AAC.01718-12. Epub 2013 Jan 7.
8
Fosfomycin-daptomycin and other fosfomycin combinations as alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
Antimicrob Agents Chemother. 2013 Jan;57(1):606-10. doi: 10.1128/AAC.01570-12. Epub 2012 Oct 22.
9
Daptomycin, fosfomycin, or both for treatment of methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model.
Antimicrob Agents Chemother. 2011 Nov;55(11):4999-5003. doi: 10.1128/AAC.00584-11. Epub 2011 Aug 22.
本文引用的文献
1
Molecular mechanisms of fosfomycin resistance in clinical isolates of Escherichia coli.
Int J Antimicrob Agents. 2010 Apr;35(4):333-7. doi: 10.1016/j.ijantimicag.2009.11.011. Epub 2010 Jan 13.
2
Fosfomycin: an old, new friend?
Eur J Clin Microbiol Infect Dis. 2010 Feb;29(2):127-42. doi: 10.1007/s10096-009-0833-2. Epub 2009 Nov 14.
3
High fosfomycin concentrations in bone and peripheral soft tissue in diabetic patients presenting with bacterial foot infection.
J Antimicrob Chemother. 2009 Sep;64(3):574-8. doi: 10.1093/jac/dkp230. Epub 2009 Jul 3.
4
Synergistic effects of aminoglycosides and fosfomycin on Pseudomonas aeruginosa in vitro and biofilm infections in a rat model.
J Antimicrob Chemother. 2009 Sep;64(3):563-6. doi: 10.1093/jac/dkp224. Epub 2009 Jun 26.
5
Clinical failures of appropriately-treated methicillin-resistant Staphylococcus aureus infections.
J Infect. 2008 Aug;57(2):110-5. doi: 10.1016/j.jinf.2008.04.003. Epub 2008 Jun 3.
6
Fosfomycin: use beyond urinary tract and gastrointestinal infections.
Clin Infect Dis. 2008 Apr 1;46(7):1069-77. doi: 10.1086/527442.
7
Efficacies of ceftobiprole medocaril and comparators in a rabbit model of osteomyelitis due to methicillin-resistant Staphylococcus aureus.
Antimicrob Agents Chemother. 2008 May;52(5):1618-22. doi: 10.1128/AAC.00638-07. Epub 2008 Mar 10.
8
Treatment of Pseudomonas aeruginosa biofilms with a combination of fluoroquinolones and fosfomycin in a rat urinary tract infection model.
J Infect Chemother. 2007 Oct;13(5):285-90. doi: 10.1007/s10156-007-0534-7. Epub 2007 Oct 30.
9
[Biological cost associated with fosfomycin resistance in Escherichia coli isolates from urinary tract infections].
Rev Esp Quimioter. 2007 Jun;20(2):211-5.
10
Synergistic effect of fosfomycin and arbekacin on a methicillin-resistant Staphylococcus aureus-induced biofilm in a rat model.
Int J Antimicrob Agents. 2005 Jan;25(1):44-50. doi: 10.1016/j.ijantimicag.2004.07.015.
Zotero 插件